ScienceDaily: Latest Science News |
- Updated clinical results show experimental agent ibrutinib as highly active in CLL patients
- Blood cancers: Studies assess genetics, modified treatment to improve outcomes, reduce toxicity
- Researchers develop novel 3-D culture system for inflammatory breast cancer
| Updated clinical results show experimental agent ibrutinib as highly active in CLL patients Posted: 08 Dec 2012 09:27 AM PST Updated results from early phase clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy. The agent, ibrutinib (PCI-32765), is the first drug designed to target Bruton's tyrosine kinase, a protein essential for CLL-cell survival and proliferation. |
| Blood cancers: Studies assess genetics, modified treatment to improve outcomes, reduce toxicity Posted: 08 Dec 2012 09:27 AM PST Research identifying genetic factors that affect survival of patients with blood cancers and evaluating the effectiveness of modified treatment strategies to improve outcomes while reducing toxicity was recently presented. |
| Researchers develop novel 3-D culture system for inflammatory breast cancer Posted: 08 Dec 2012 09:27 AM PST Inflammatory breast cancer is a very rare and aggressive disease. To understand how this type of cancer spreads, it's crucial to characterize the interactions between cancer cells and their 3-D environment. Researchers have developed a novel, 3-D culture system that mimics the environment surrounding these cancer cells. This model could be used to test new anticancer drugs capable of inhibiting the spread of IBC tumors. |
| You are subscribed to email updates from ScienceDaily: Latest Science News To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
No comments:
Post a Comment